Ryan K. Shields, PharmD, MS
Ryan K. Shields, PharmD, MS
Associate Professor of Medicine, University of Pittsburgh
Verified email at upmc.edu
Title
Cited by
Cited by
Year
Colistin-Resistant Acinetobacter baumannii: Beyond Carbapenem Resistance
ZA Qureshi, LE Hittle, JA O'Hara, JI Rivera, A Syed, RK Shields, ...
Clinical infectious diseases 60 (9), 1295-1303, 2015
2812015
Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections
RK Shields, BA Potoski, G Haidar, B Hao, Y Doi, L Chen, EG Press, ...
Clinical Infectious Diseases 63 (12), 1615-1618, 2016
2682016
Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections
RK Shields, L Chen, S Cheng, KD Chavda, EG Press, A Snyder, ...
Antimicrobial agents and chemotherapy 61 (3), 2017
2582017
Performance of Candida Real-time Polymerase Chain Reaction, β-D-Glucan Assay, and Blood Cultures in the Diagnosis of Invasive Candidiasis
MH Nguyen, MC Wissel, RK Shields, MA Salomoni, B Hao, EG Press, ...
Clinical infectious diseases 54 (9), 1240-1248, 2012
2582012
Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia
RK Shields, MH Nguyen, L Chen, EG Press, BA Potoski, RV Marini, Y Doi, ...
Antimicrobial agents and chemotherapy 61 (8), 2017
2182017
Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance
G Haidar, NJ Philips, RK Shields, D Snyder, S Cheng, BA Potoski, B Hao, ...
Clinical Infectious Diseases 65 (1), 110-120, 2017
1572017
The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata
RK Shields, MH Nguyen, EG Press, AL Kwa, S Cheng, C Du, CJ Clancy
Antimicrobial agents and chemotherapy 56 (9), 4862-4869, 2012
1462012
Comparison of an Aspergillus Real-time Polymerase Chain Reaction Assay With Galactomannan Testing of Bronchoalvelolar Lavage Fluid for the Diagnosis of …
ML Luong, CJ Clancy, A Vadnerkar, EJ Kwak, FP Silveira, MC Wissel, ...
Clinical Infectious Diseases 52 (10), 1218-1226, 2011
1312011
Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients
RK Shields, CJ Clancy, LM Gillis, EJ Kwak, FP Silveira, RCA Massih, ...
PloS one 7 (12), e52349, 2012
1242012
Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and …
D Mitsani, MH Nguyen, RK Shields, Y Toyoda, EJ Kwak, FP Silveira, ...
Antimicrobial agents and chemotherapy 56 (5), 2371-2377, 2012
1222012
Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents
R Almaghrabi, CJ Clancy, Y Doi, B Hao, L Chen, RK Shields, EG Press, ...
Antimicrobial agents and chemotherapy 58 (8), 4443-4451, 2014
1052014
Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae …
RK Shields, MH Nguyen, L Chen, EG Press, BN Kreiswirth, CJ Clancy
Antimicrobial agents and chemotherapy 62 (5), 2018
1002018
Mutations in blaKPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum β-lactamases
G Haidar, CJ Clancy, RK Shields, B Hao, S Cheng, MH Nguyen
Antimicrobial agents and chemotherapy 61 (5), 2017
992017
Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure
RK Shields, MH Nguyen, EG Press, CL Updike, CJ Clancy
Antimicrobial agents and chemotherapy 57 (8), 3528-3535, 2013
942013
Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against …
RK Shields, CJ Clancy, B Hao, L Chen, EG Press, NM Iovine, ...
Antimicrobial agents and chemotherapy 59 (9), 5793-5797, 2015
912015
Epidemiology and Molecular Characterization of Bacteremia Due to Carbapenem‐Resistant Klebsiella pneumoniae in Transplant Recipients
CJ Clancy, L Chen, RK Shields, Y Zhao, S Cheng, KD Chavda, B Hao, ...
American Journal of Transplantation 13 (10), 2619-2633, 2013
882013
Intra-abdominal candidiasis: the importance of early source control and antifungal treatment
P Vergidis, CJ Clancy, RK Shields, SY Park, BN Wildfeuer, RL Simmons, ...
PLoS One 11 (4), e0153247, 2016
852016
The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae
MG Jernigan, EG Press, MH Nguyen, CJ Clancy, RK Shields
Antimicrobial agents and chemotherapy 56 (6), 3395-3398, 2012
852012
Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae
G Haidar, CJ Clancy, L Chen, P Samanta, RK Shields, BN Kreiswirth, ...
Antimicrobial agents and chemotherapy 61 (9), 2017
792017
Abdominal candidiasis is a hidden reservoir of echinocandin resistance
RK Shields, MH Nguyen, EG Press, CJ Clancy
Antimicrobial agents and chemotherapy 58 (12), 7601-7605, 2014
792014
The system can't perform the operation now. Try again later.
Articles 1–20